Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II, open label, single arm study on safety, tolerability and anti -tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma

Next Previous
X
Search
Trial Profile

A phase I/II, open label, single arm study on safety, tolerability and anti -tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orellanine (Primary)
  • Indications Carcinoma; Renal cancer
  • Focus Adverse reactions; First in man
  • Acronyms Oncorella-1
  • Sponsors Oncorena Holding

    • Most Recent Events

    • 16 Apr 2024 Planned number of patients changed from 40 to 50.
    • 27 Jan 2024 Trial design, presented at the 2024 Genitourinary Cancers Symposium
    • 08 Aug 2023 According to an Oncorena Holding media release, company announced first patient has been treated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top